Background: Colorectal neuroendocrine tumors are rare and have a heterogeneous clinical representation and variable prognosis. High grade neuroendocrine tumors (NETs) are characterized by destructive and aggressive growth, followed by rapid spread. For this purpose, SPECT/CT with 99mTc-Tektrotyd is very useful for imaging and staging of NETs. Case Report: A 50-year-old man with a huge metastatic liver from an unknown neuroendocrine tumor (NET). SPECT/CT with 99mTc-Tektrotyd was performed in this patient, it showed a huge metastatic hepatomegaly compressing neighboring organs with bone metastases, and also revealed the primary colon tumor. Discussion and Conclusion: In recent decades, the incidence and prevalence of neuroendocrine tumors (NETs), especially those of the colorectal segments, have been increasing. 99mTc-EDDA/HYNIC-TOC (Tektrotyd?) was introduced into the market and its use has been approved for scintigraphic imaging of patients with NETs and other SSTR-positive tumors. It provides in vivo metabolic data related to the over-expression of Somatostatin Receptors (SSTRs) and also predicts response to peptide receptor radionuclide therapy (PRRT).
References
[1]
Ramage, J.K., De Herder, W.W., Delle, F.G., Ferolla, P., Ferone, D., et al. (2016) ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. Neuroendocrinology, 103, 139-143. https://doi.org/10.1159/000443166
[2]
Yoshida, T., Kamimura, K., Hosaka, K., Doumori, K., Oka, H., Sato, A., Fukuhara, Y., Watanabe, S., Sato, T., Yoshikawa, A., Tomidokoro, T. and Terai, S. (2019) Colorectal Neuroendocrine Carcinoma: A Case Report and Review of the Literature. World Journal of Clinical Cases, 7, 1865-1875. https://doi.org/10.12998/wjcc.v7.i14.1865
[3]
Mukherjee, A., Kordea, A., Shintoc, A., Dev Sarmab, H., Kamaleswaranc, K. and Dasha, A. (2019) Studies on Batch Formulation of a Freeze Dried Kit for the Preparation of 99mTc-HYNIC-TATE for Imaging Neuroendocrine Tumors. Applied Radiation and Isotopes, 145, 180-186. https://doi.org/10.1016/j.apradiso.2018.12.027
[4]
Cloyd, J.M., Ejaz, A., Konda, B., Makary, M.S., et al. (2020) Neuroendocrine Liver Metastases: A Contemporary Review of Treatment Strategies. The Hepatobiliary Surgery and Nutrition, 9, 440-451. https://doi.org/10.21037/hbsn.2020.04.02
[5]
Mihalache, O., Doran, H., Poiană, C., Bîrligea, A., Cîrstea, M.O. and Pătraşcu, T. (2019) Pancreatic Neuroendocrine Tumors—Case Series and Literature Review. Chirurgia, 114, 630-638. https://doi.org/10.21614/chirurgia.114.5.630
[6]
André, T.R., Brito, M., Freire, J.G. and Moreira, A. (2018) Rectal and Anal Canal Neuroendocrine Tumours. Journal of Gastrointestinal Oncology, 9, 354-357. https://doi.org/10.21037/jgo.2017.10.01
[7]
Mussan-Chelminsky, G., Vidal-González, P., Nunez-García, E., Valencia-García, L.C. and Márquez-Ugalde, M.A. (2015) Intestinal Carcinoid Tumour: Case Report. Cirugía y Cirujanos, 83, 438-441. https://doi.org/10.1016/j.circen.2015.10.015
[8]
Frilling, A., Sotiropoulos, G.C., Li, J., Kornasiewicz, O. and Plockinger, U. (2010) Multimodal Management of Neuroendocrine Liver Metastases. HPB, 12, 361-379. https://doi.org/10.1111/j.1477-2574.2010.00175.x
[9]
Frilling, A., Modlin, I.M., Kidd, M., et al. (2014) Recommendations for Management of Patients with Neuroendocrine Liver Metastases. The Lancet Oncology, 15, 8-21. https://doi.org/10.1016/S1470-2045(13)70362-0
[10]
Tsilimigras, D.I., Squires, M.H., Cloyd, J.M., et al. (2019) Treatment Strategies for Neuroendocrine Liver Metastases: An Update. Expert Opinion on Orphan Drugs, 7, 327-335. https://doi.org/10.1080/21678707.2019.1651639
[11]
Frilling, A. and Clift, A.K. (2015) Therapeutic Strategies for Neuroendocrine Liver Metastases. Cancer, 121, 1172-1186. https://doi.org/10.1002/cncr.28760
[12]
Theodoropoulou, M. and Stalla, G.K. (2013) Somatostatin Receptors: From Signaling to Clinical Practice. Frontiers in Neuroen-Docrinology, 34, 228-252. https://doi.org/10.1016/j.yfrne.2013.07.005
[13]
Briganti, V., Cuccurullo, V., Berti, V., Di Stasio, G.D., Linguanti, F., Mungai, F. and Mansi, L. (2000) 99mTc-EDDA/HYNIC-TOC Is a New Opportunity in Neuroendocrine Tumors of the Lung. Current Radiopharmaceuticals, 13, 166-176. https://doi.org/10.2174/1874471013666191230143610
